Dexafree ud 0.1

Postoperative examinations were performed during study visits on day 1, week 1, 3, 6, month 3, 6 and 12, or more frequently if clinically indicated. Postoperative medications included unpreserved topical dexamethasone (Dexafree ® UD 0.1%) 8 times daily and tapered over 6 weeks and ofloxacin (Floxal ® UD, Bausch and Lomb, Zug, Switzerland) 4 times daily.
Postoperative adjustments to reduce intraluminal outflow resistance and IOP were performed according to the following time points:  ≥ 4 weeks postoperatively: argon laser suture lysis (LSL) of the nylon ligature suture (when present), using a Hoskins lens.  6-12 weeks postoperatively: partial stent removal (P-SR), the occluding stent was retracted by 5 mm. This was only performed if IOP remained uncontrolled despite maximal medications.  ≥12weeks postoperatively: complete stent removal (C-SR) was performed. In cases of neovascular glaucoma, uveitis or previous cyclodestructive procedures (risk factors for hypotony) P-SR was performed as a first procedure and followed by C-SR if required  Stent removals were not performed when IOP dropped to ≤10 mmHg without glaucoma medications.

Postoperative management included unpreserved topical dexamethasone (Dexafree® UD 0.1%) 8 times daily, tapered over 4-6 weeks and ofloxacin (Floxal® UD, Bausch and Lomb, Zug, Switzerland) 4 times daily. Argon laser suture lysis (LSL) of the nylon ligature suture was performed using a Hoskins lens ≥ 1 month after the surgery if IOP lowering was clinically required. If sufficient IOP reduction was not obtained after 12 weeks, the occluding stent was either retracted or removed depending on risk factors for hypotony.